Sweden-based Betagenon AB has appointed James Hall as its new chief executive officer, and Gunnar Olsson as chairman of the board of directors as it advances the development of new therapies for metabolic disorders. Both executives previously held management positions at AstraZeneca Plc. Mr Hall was head of global marketing for cardiovascular (CV) and gastrointestinal therapy (GI) medicines, while Dr Olsson held senior roles in global R&D and led the CV and GI therapy division. Dr Olsson was certified in cardiology and internal medicine at hospitals associated with the Karolinska Institutet.
Mr Hall holds a DPhil in cell physiology from Oxford University in the UK.
Betagenon announced the appointments on 27 May 2021.
Copyright 2021 Evernow Publishing Ltd